Document is current
Any future updates will be listed below
-
Authors
Elafros, Melissa A. https://orcid.org/0000-0002-4511-201X
Callaghan, Brian C. https://orcid.org/0000-0002-8885-6748
Skolarus, Lesli E. https://orcid.org/0000-0002-3088-9838
Vileikyte, Loretta https://orcid.org/0000-0001-8514-2128
Lawrenson, John G https://orcid.org/0000-0002-2031-6390
Feldman, Eva L. https://orcid.org/0000-0002-9162-2694
-
Funding
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (5R25NS089450, R01DK130913)
National Center for Advancing Translational Sciences (UL1TR002240)
National Institute of Diabetes and Digestive and Kidney Diseases (P30-DK-02926, P30-DK089503, R01DK115687, 1R43DK126592-01A1, R01DK129320, R24 DK082841)
Juvenile Diabetes Research Foundation United States of America (5COE-2019-861-S-B, 5COE-2019-861-S-B)
National Institute on Minority Health and Health Disparities (R01MD011516, U01MD010579)
National Institute on Aging (R21AG071796, R01AG059733)
National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care Yorkshire and Humber (PR-R20-0318-22001)
International Diabetic Neuropathy Consortium (NNF14OC0011633)
the Nathan and Rose Milstein Research Fund (the Nathan and Rose Milstein Research Fund)
Sinai Medical Staff Foundation (Sinai Medical Staff Foundation)
A. Alfred Taubman Medical Research Institute (A. Alfred Taubman Medical Research Institute)
NeuroNetwork for Emerging Therapies (NeuroNetwork for Emerging Therapies)
- License Information
-
More Information
Article History
Accepted: 31 August 2022
First Online: 2 November 2022
Disclosures
: Dr. Callaghan consults for DynaMed, performs medical legal consultations including consultations for the Vaccine Injury Compensation Program, and receives research funding from the American Academy of Neurology.
: The authors have no conflicts of interest to disclose.
: Not applicable.
: Not applicable.
